Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Company Overview

Lisata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies intended to improve the treatment of solid tumors. The company’s approach centers on tumor-penetrating peptides designed to selectively target the tumor microenvironment and help therapeutic agents reach cancer cells more effectively.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is designed to activate the CendR pathway, which may increase the penetration and distribution of co-administered anticancer treatments within tumors. The company has studied certepetide in combination with chemotherapy and other cancer therapies, including in pancreatic cancer and other advanced solid tumors. The product remains investigational and is not approved for commercial use.

The company was formerly known as Cend Therapeutics and adopted the Lisata Therapeutics name in 2022. Its development programs are conducted through collaborations and clinical studies involving research institutions, biotechnology companies and pharmaceutical partners in the United States and other regions. Lisata is headquartered in San Diego, California, and is led by President and Chief Executive Officer David J. Mazzo.

Key Stats

• Today's Range: $1.13 to $1.22
• 50-Day Range: $0.99 to $1.90
• 52-Week Range: $0.99 to $5.07
• Volume: 403,918 shs
• Average Volume: 191,081 shs
• Market Capitalization: $11.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Lisata Therapeutics Stock Analysis - MarketRank™

Lisata Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 814th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Lisata Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lisata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lisata Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lisata Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lisata Therapeutics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.02% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 0.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently increased by 16.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lisata Therapeutics does not currently pay a dividend.

Dividend Growth

Lisata Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.25

News Sentiment

Lisata Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Lisata Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for LSTA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

1 people have added Lisata Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of Lisata Therapeutics is held by insiders.

Percentage Held by Institutions

8.94% of the stock of Lisata Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LSTA
• CIK: 320017
• Web: www.lisata.com
• Phone: (908) 229-2590
• Fax: 646-514-7787
• Employees: 21
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.59 million
• Net Margins: N/A
• Pretax Margin: -15,008.00%
• Return on Equity: -116.08%
• Return on Assets: -90.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.69
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: $170 thousand
• Price / Sales: 64.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 9,010,000
• Free Float: 8,146,000
• Market Cap: $10.90 million
• Optionable: Not Optionable
• Beta: 0.94